American Heart Association (AHA) diagnostic criteria[1]McCrindle BW, Rowley AH, Newburger JW, et al; American Heart Association. Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association. Circulation. 2017 Apr 25;135(17):e927-99.
https://www.ahajournals.org/doi/full/10.1161/cir.0000000000000484
http://www.ncbi.nlm.nih.gov/pubmed/28356445?tool=bestpractice.com
[28]Jone PN, Tremoulet A, Choueiter N, et al. Update on diagnosis and management of Kawasaki disease: a scientific statement from the American Heart Association. Circulation. 2024 Dec 3;150(23):e481-500.
https://www.ahajournals.org/doi/10.1161/CIR.0000000000001295
http://www.ncbi.nlm.nih.gov/pubmed/39534969?tool=bestpractice.com
Diagnosis is based on clinical signs and symptoms. There are no unique laboratory diagnostic tests for the disease. The principal signs were recognised and reported in 1974, and these criteria have been updated by the AHA (Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease; the Council on Cardiovascular Disease in the Young) and endorsed by the American Academy of Pediatrics.[1]McCrindle BW, Rowley AH, Newburger JW, et al; American Heart Association. Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association. Circulation. 2017 Apr 25;135(17):e927-99.
https://www.ahajournals.org/doi/full/10.1161/cir.0000000000000484
http://www.ncbi.nlm.nih.gov/pubmed/28356445?tool=bestpractice.com
[28]Jone PN, Tremoulet A, Choueiter N, et al. Update on diagnosis and management of Kawasaki disease: a scientific statement from the American Heart Association. Circulation. 2024 Dec 3;150(23):e481-500.
https://www.ahajournals.org/doi/10.1161/CIR.0000000000001295
http://www.ncbi.nlm.nih.gov/pubmed/39534969?tool=bestpractice.com
[30]Kawasaki T, Kosaki T, Okawa S, et al. A new infantile acute febrile mucocutaneous lymph node syndrome (MLNS) prevailing in Japan. Pediatrics. 1974 Sep;54(3):271-6.
http://www.ncbi.nlm.nih.gov/pubmed/4153258?tool=bestpractice.com
Patients with classic KD must have 4 days of fever that is refractory to antibiotic therapy (if given) and at least four of the following five signs and symptoms:
At least one of the following mucous-membrane changes:
Injected lips (and/or dryness, fissuring, peeling, cracking, and bleeding of the lips)
Injected pharynx
Strawberry tongue (with erythema and prominent fungiform papillae)
At least one of the following extremity changes:
Cervical lymphadenopathy (at least one lymph node >1.5 cm in diameter), usually unilateral.
Risk stratification for relative risk of future myocardial ischaemia has also been proposed:[1]McCrindle BW, Rowley AH, Newburger JW, et al; American Heart Association. Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association. Circulation. 2017 Apr 25;135(17):e927-99.
https://www.ahajournals.org/doi/full/10.1161/cir.0000000000000484
http://www.ncbi.nlm.nih.gov/pubmed/28356445?tool=bestpractice.com
Low-risk level: patients without detectable coronary artery aneurysms (CAAs)
Low-moderate-risk level: patients with regressed CAAs
High-risk level: patients with angiographical evidence of large or giant aneurysms, or coronary obstruction.
Although not part of the formal diagnostic criteria, AHA guidelines emphasise the utility of Z scores to reflect standardised dimensions of coronary arteries normalised for body surface area (BSA) to allow for classification and comparisons across time and populations.[1]McCrindle BW, Rowley AH, Newburger JW, et al; American Heart Association. Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association. Circulation. 2017 Apr 25;135(17):e927-99.
https://www.ahajournals.org/doi/full/10.1161/cir.0000000000000484
http://www.ncbi.nlm.nih.gov/pubmed/28356445?tool=bestpractice.com
[28]Jone PN, Tremoulet A, Choueiter N, et al. Update on diagnosis and management of Kawasaki disease: a scientific statement from the American Heart Association. Circulation. 2024 Dec 3;150(23):e481-500.
https://www.ahajournals.org/doi/10.1161/CIR.0000000000001295
http://www.ncbi.nlm.nih.gov/pubmed/39534969?tool=bestpractice.com
[49]Manlhiot C, Millar K, Golding F, et al. Improved classification of coronary artery abnormalities based only on coronary artery z-scores after Kawasaki disease. Pediatr Cardiol. 2009 Dec 19;31(2):242-9.
http://www.ncbi.nlm.nih.gov/pubmed/20024653?tool=bestpractice.com
The guidelines suggest using maximal past and current Z scores and any other additional clinical features when deciding on risk stratification for long-term management.[1]McCrindle BW, Rowley AH, Newburger JW, et al; American Heart Association. Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association. Circulation. 2017 Apr 25;135(17):e927-99.
https://www.ahajournals.org/doi/full/10.1161/cir.0000000000000484
http://www.ncbi.nlm.nih.gov/pubmed/28356445?tool=bestpractice.com
[28]Jone PN, Tremoulet A, Choueiter N, et al. Update on diagnosis and management of Kawasaki disease: a scientific statement from the American Heart Association. Circulation. 2024 Dec 3;150(23):e481-500.
https://www.ahajournals.org/doi/10.1161/CIR.0000000000001295
http://www.ncbi.nlm.nih.gov/pubmed/39534969?tool=bestpractice.com
Z-score classification[1]McCrindle BW, Rowley AH, Newburger JW, et al; American Heart Association. Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association. Circulation. 2017 Apr 25;135(17):e927-99.
https://www.ahajournals.org/doi/full/10.1161/cir.0000000000000484
http://www.ncbi.nlm.nih.gov/pubmed/28356445?tool=bestpractice.com
[28]Jone PN, Tremoulet A, Choueiter N, et al. Update on diagnosis and management of Kawasaki disease: a scientific statement from the American Heart Association. Circulation. 2024 Dec 3;150(23):e481-500.
https://www.ahajournals.org/doi/10.1161/CIR.0000000000001295
http://www.ncbi.nlm.nih.gov/pubmed/39534969?tool=bestpractice.com
No involvement: always <2
Dilation only: 2.0 to <2.5
Small aneurysm: ≥2.5 to <5.0
Medium aneurysm: ≥5 to <10, and absolute dimension <8 mm
Large or giant aneurysm: ≥10, or absolute dimension ≥8 mm.
Additional clinical features indicating risk of myocardial ischaemia include greater total number, length, number of branches, and distal location of aneurysms; structural and functional vessel wall abnormalities; poor collateral vessels; previous revascularisation, coronary artery thrombosis, or myocardial infarction; and ventricular dysfunction.[1]McCrindle BW, Rowley AH, Newburger JW, et al; American Heart Association. Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association. Circulation. 2017 Apr 25;135(17):e927-99.
https://www.ahajournals.org/doi/full/10.1161/cir.0000000000000484
http://www.ncbi.nlm.nih.gov/pubmed/28356445?tool=bestpractice.com